ProfileGDS5678 / 1419637_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 83% 82% 84% 84% 85% 86% 84% 83% 82% 83% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.871982
GSM967853U87-EV human glioblastoma xenograft - Control 25.9273182
GSM967854U87-EV human glioblastoma xenograft - Control 36.0381883
GSM967855U87-EV human glioblastoma xenograft - Control 46.1341682
GSM967856U87-EV human glioblastoma xenograft - Control 56.2354484
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9477584
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2601785
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5337286
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2091984
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1200783
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9271682
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.177883
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.343385
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1509184